TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Benzinga Logo Benzinga By Business Wire
Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

MoonLake Immunotherapeutics announced disappointing Phase 3 results for its drug candidate sonelokimab, causing an 89.9% stock drop after failing to match competitor's drug efficacy. A class action lawsuit alleges the company made misleading statements about its drug's potential.

Insights
GLNK   positive

Mentioned as a strategic partner providing oracle services, indicating a collaborative and supportive relationship with Streamex


MLTX   negative

Stock price dropped 89.9% after failed drug trial, facing potential securities fraud lawsuit, and allegations of misleading investors about drug candidate's capabilities